Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medlive Technology Co., Ltd. (2192.HK)
Beijing, CN
Medlive Technology Co., Ltd., along with its affiliated entities, manages a digital platform tailored for medical professionals, serving both the Chinese mainland and international markets. Through its comprehensive platform, the company delivers a precision marketing and corporate solution encompassing a wide array of services. These include project oversight, clinical supervision, handling of clinical data, biostatistical analysis, drafting of study protocols, medical supervision, patient enrollment, and system support. Furthermore, it offers digital market intelligence, electronic data collection, real-world evidence generation, and the development of application software. Medlive also provides a medical knowledge solution focused on continuing medical education and tools for clinical decision-making, which involves licensing specialized software to physicians and other registered users, including various healthcare practitioners and pharmaceutical corporations. An intelligent patient management solution is another core offering, delivering chronic disease management services that cover online consultations, prescription fulfillment, and patient care facilitated by an Internet hospital. Additionally, it provides condition-specific patient education, involving the creation of content, development of specialized software, and associated support services. Originally established in 1996 as Kingyee Co., Limited, the enterprise adopted the name Medlive Technology Co., Ltd. in 2021. Its corporate headquarters are located in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.20% | -4.25% | -14.00% | -17.35% | -27.51% | -23.40% | -40.84% | +5.69% | -76.03% | -76.03% | -76.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+15.0% ★ Q4'25: +38.4% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%+4.7% Q4'25: +20.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+16.2% Q4'25: +26.1% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+26.1% ★ Q4'25: +30.1% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+13.3% ★ Q4'25: +31.6% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+0.1% Q4'25: +0.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.06× ★ Q4'25: 0.02× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
284.44M
est: 347.84M (-18.2%)
|
314.05M
est: 353.55M (-11.2%)
|
412.00M
est: 448.30M (-8.1%)
|
558.46M
est: 546.80M (+2.1%)
|
642.16M
est: 644.63M (-0.4%)
|
781.04M
757.48M – 819.48M
+21.2% YoY
|
916.23M
852.19M – 1.01B
+17.3% YoY
|
1.07B
1.02B – 1.16B
+17.2% YoY
|
| EBITDA |
76.61M
est: 146.22M (-47.6%)
|
144.56M
est: 148.62M (-2.7%)
|
262.86M
est: 166.54M (+57.8%)
|
121.35M
est: 203.13M (-40.3%)
|
174.99M
est: 239.47M (-26.9%)
|
290.15M
281.40M – 304.43M
+21.2% YoY
|
340.37M
316.58M – 376.82M
+17.3% YoY
|
398.85M
378.26M – 430.95M
+17.2% YoY
|
| EBIT |
70.46M
est: 138.92M (-49.3%)
|
135.57M
est: 141.21M (-4.0%)
|
253.49M
est: 158.30M (+60.1%)
|
117.44M
est: 193.08M (-39.2%)
|
167.36M
est: 227.63M (-26.5%)
|
275.80M
267.48M – 289.37M
+21.2% YoY
|
323.53M
300.92M – 358.19M
+17.3% YoY
|
379.12M
359.55M – 409.63M
+17.2% YoY
|
| Net Income |
40.62M
est: 126.51M (-67.9%)
|
117.32M
est: 116.81M (+0.4%)
|
242.30M
est: 270.04M (-10.3%)
|
315.15M
est: 295.34M (+6.7%)
|
334.34M
est: 331.58M (+0.8%)
|
371.85M
364.70M – 379.00M
+12.1% YoY
|
406.65M
391.21M – 422.10M
+9.4% YoY
|
431.91M
418.85M – 549.40M
+6.2% YoY
|
| SGA |
127.67M
est: 127.95M (-0.2%)
|
151.34M
est: 130.05M (+16.4%)
|
177.26M
est: 185.88M (-4.6%)
|
208.99M
est: 226.72M (-7.8%)
|
217.04M
est: 267.29M (-18.8%)
|
323.85M
314.08M – 339.79M
+21.2% YoY
|
379.91M
353.35M – 420.59M
+17.3% YoY
|
445.18M
422.20M – 481.00M
+17.2% YoY
|
| EPS |
0.07
est: 0.17 (-61.6%)
|
0.16
est: 0.16 (+1.0%)
|
0.33
est: 0.37 (-11.2%)
|
0.43
est: 0.40 (+7.5%)
|
0.46
est: 0.45 (+2.2%)
|
0.50
0.50 – 0.51
+12.1% YoY
|
0.55
0.53 – 0.57
+9.4% YoY
|
0.66
0.57 – 0.75
+19.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Matthews Emerging Markets Sustainable Future Active ETF EMSF EMSF | 0.26% | 118.0K | 0.79% |
| 2 | iShares MSCI China Small-Cap ETF ECNS | 0.13% | 87.4K | 0.59% |
| 3 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 159.2K | 0.65% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.01% | 10.9K | 0.74% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 43.3K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 56.6K | 0.55% |
| 7 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.01% | 158.1K | 0.09% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 9.1K | 0.42% |
| 9 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.00% | 49.2K | 0.28% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 47.9K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Liping Tian | Chairwoman & Chief Executive Officer | 2M | female |
| Lixin Tian | President, Head of Medical Information Science Research Unit & Executive Director | 2M | male |
| Lijun Tian | Vice President, Deputy Head of Medical Information Science Research Unit & Executive Director | 2M | male |
| Xin Zhou | Vice President & Executive Director | 921.0K | female |
| Jiang Nan | Medical Director, Chief Editor-Content Team & Dy. Head of Medical Information Science Research Unit | — | male |
| Yanling Yang | Company Secretary | — | female |
| Juan Liu | Chief Client Officer & Assistant to Chairwoman | — | female |
| Lingdi Liu | Executive | — | female |
| Xiaofeng Zhang | Executive | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2192.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
